Brian Rosen - Novavax Senior Vice President - Commercial Strategy
| NVV1 Stock | EUR 8.38 0.53 5.95% |
Insider
Brian Rosen is Senior Vice President - Commercial Strategy of Novavax since 2018.
| Tenure | 6 years |
| Phone | 240 268 2000 |
| Web | https://www.novavax.com |
Novavax Management Efficiency
The company has return on total asset (ROA) of (0.317) % which means that it has lost $0.317 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (8.982) %, meaning that it generated substantial loss on money invested by shareholders. Novavax's management efficiency ratios could be used to measure how well Novavax manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Melissa Moore | Moderna | N/A | |
| Janet Hoogstraate | Valneva SE | N/A | |
| Malte Greune | CureVac NV | 58 | |
| Stephen Berenson | Moderna | 58 | |
| Sean Marett | BioNTech SE | 58 | |
| Antony Blanc | CureVac NV | 53 | |
| Sarah Fakih | CureVac NV | N/A | |
| Pierre BSc | CureVac NV | 48 | |
| Paul Sagan | Moderna | 59 | |
| Sierk Poetting | BioNTech SE | 50 | |
| Dipal Patel | Valneva SE | N/A | |
| Tal Zaks | Moderna | 53 | |
| Thomas Casdagli | Valneva SE | 42 | |
| Ryan Richardson | BioNTech SE | 44 | |
| Stephen MD | Moderna | 47 | |
| Slavica StevanovicHeck | CureVac NV | N/A | |
| Joshua Drumm | Valneva SE | N/A | |
| Noubar Afeyan | Moderna | 60 | |
| Sylke Maas | BioNTech SE | N/A | |
| Lavina CFA | Moderna | N/A | |
| Johanna Pattenier | Valneva SE | N/A | |
Management Performance
| Return On Equity | -8.98 | |||
| Return On Asset | -0.32 |
Novavax Leadership Team
Elected by the shareholders, the Novavax's board of directors comprises two types of representatives: Novavax inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novavax. The board's role is to monitor Novavax's management team and ensure that shareholders' interests are well served. Novavax's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novavax's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA BS, Exec Officer | ||
| Jody Lichaa, Senior Vice President - Quality Assurance | ||
| Stanley Erck, President, Chief Executive Officer, Director | ||
| Ben Machielse, Executive Vice President - CMC | ||
| Michael McManus, Independent Director | ||
| Brian Webb, Senior Vice President - Manufacturing | ||
| Rick Crowley, Chief Operating Officer, Executive Vice President | ||
| John Herrmann, Executive Vice President Chief Legal Officer | ||
| Filip Dubovsky, Senior Vice President Chief Medical Officer | ||
| Rachel King, Independent Director | ||
| Gary Evans, Independent Director | ||
| Margaret McGlynn, Independent Director | ||
| Jill Hoyt, Chief Human Resource Officer, Executive Vice President | ||
| Erika Trahan, Associate PR | ||
| Henrietta Ukwu, Senior Vice President Chief Regulatory and Quality Officer | ||
| Frank Czworka, Senior Vice President - Global Sales | ||
| Gregg Alton, Director | ||
| James CFA, CFO VP | ||
| Rajiv Modi, Director | ||
| John Trizzino, Executive Vice President, Chief Business Officer, Chief Financial Officer and Treasurer | ||
| JD Esq, VP Officer | ||
| Brian Rosen, Senior Vice President - Commercial Strategy | ||
| Richard Crowley, Ex COO | ||
| Gregory Covino, Chief Financial Officer, Executive Vice President | ||
| Silvia Taylor, Senior Vice President of Investor Relations and Corporate Affairs | ||
| John III, Chief VP | ||
| Biegie Lee, VP Officer | ||
| Gale Smith, VP Scientist | ||
| James Young, Independent Chairman of the Board | ||
| Gregory Glenn, President Research and Development | ||
| David Mott, Independent Director | ||
| Madelyn Caltabiano, Senior Vice President - Global Program Management | ||
| Richard Douglas, Independent Director |
Novavax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novavax a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -8.98 | |||
| Return On Asset | -0.32 | |||
| Profit Margin | (0.72) % | |||
| Operating Margin | (0.66) % | |||
| Current Valuation | 484 M | |||
| Shares Outstanding | 85 M | |||
| Shares Owned By Insiders | 0.45 % | |||
| Shares Owned By Institutions | 62.33 % | |||
| Price To Book | 72.32 X | |||
| Price To Sales | 0.45 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Novavax Stock
When determining whether Novavax offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novavax's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novavax Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novavax Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Novavax Stock please use our How to Invest in Novavax guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.